Aptinyx Inc(APTX)stock report

Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company’s compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company’s compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.

Finance:
Market Cap:208.7M; Shares Outstanding:45.4M; Short Interest: 1.01%; Q3 2019(9/30/19): Cash 114M Loss 14.79M

EPS and Sales:
https://finance.yahoo.com/quote/APTX/financials?p=APTX

Date EPS % last year % last quarter
2018.12.31 -2.64 57.21% -6.45%
2019.3.31 -0.5 76.96% 81.06%
2019.6.30 -0.86 78.23% -72.00%
2019.9.30 -1.3 47.58% -51.16%

 

Date Sales % last year % last quarter
2018.12.31 6.57M 32.49% 18.59%
2019.3.31 0.89M -63.88% -86.45%
2019.6.30 1.82M -60.48% 104.49%
2019.9.30 2.75M -50.3 51.10%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=APTX&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/APTX/institutional-ownership/

2020.01.21:
Total institutions: 67,Reduced 1
Shares hold: 17485.6k shares.no change
shares% hold: 39.88%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/APTX/price-targe

Leave a Reply